ImmuCell Corporation — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; unaudited. ImmuCell is an animal-health company whose sales are concentrated in First Defense products for preventing scours in calves. Its Mastitis segment is developing Re-Tain for subclinical mastitis; U.S. sales require FDA approval.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 |
|---|---|---|
| Product sales | $3.447 million | $6.000 million |
| Gross margin | $301,000; 9% of sales | $3.103 million; 52% of sales |
| Operating income (loss) | ($2.256 million) | $571,000 |
| Net income (loss) | ($2.315 million); ($0.30) per share | $513,000; $0.07 per diluted share |
| Cash from operating activities | ($2.762 million) | $639,000 |
| Capital expenditures | $682,000 | $807,000 |
| Cash at period end | $3.096 million | $11.817 million |
Sales fell 43% year over year, primarily because production was slowed to investigate and remediate contamination, not because management reported a decline in demand. The resulting sharp decline in volume, fixed-cost absorption and a $129,000 contamination-related cost-of-goods-sold charge drove the gross-margin deterioration. The filing also reports $262,527 of scrapped inventory reflected in the March 31 inventory balance.
At March 31, current assets were $12.248 million and current liabilities were $3.838 million, including a $1.0 million line-of-credit draw. Net working capital was approximately $8.410 million. Debt obligations, net of issuance costs, were about $9.981 million, plus the $1.0 million line of credit; the company repaid that line in full at the beginning of Q2. Debt is principally fixed-rate, secured bank borrowing, with additional subordinated Maine Technology Institute loans. Management said cash and expected product-sale gross margin should fund planned operations for at least 12 months from the filing date.
Material changes and operating developments
- Q1 sales declined about $2.553 million from the prior-year quarter. First Defense represented 99% of Q1 sales. The United States accounted for 87% of sales, versus 92% a year earlier.
- Gross margin fell from $3.103 million to $301,000. The company cited the production slowdown, lower sales volume and fixed-cost under-absorption, as well as contamination-related scrap.
- Cash declined $2.696 million from year-end 2022. Operating cash use reflected the net loss and working-capital movements; financing included the $1.0 million line-of-credit draw.
- The order backlog was approximately $7.5 million at March 31 and approximately $8 million at May 3. Management cautioned that it includes old, potentially redundant or cancellable orders and may not convert fully to sales.
- Two distributors represented 77% of Q1 sales; two significant customers represented 77% of period-end receivables. Customer concentration is a material exposure.
Outlook, commentary and risks
- First Defense: Management reported improving quality-test results after the January contamination issue and said production was rebuilding. Its goal, once remediation is complete, is to produce at least $6 million of product per quarter, equivalent to approximately 80% of the stated $30 million annual capacity. The company aims to exceed approximately $19 million of annual sales as soon as possible and has described a longer-term goal of exceeding $35 million in annual sales within five years after Re-Tain’s launch. These are goals, not guarantees.
- Capacity spending: The company reported approximately $30 million of annual First Defense capacity, with potential expansion to approximately $40 million. In response to lost Q1 gross margin, it deferred approximately $1.687 million of Re-Tain facility spending and $4.2 million of Project H spending for the time being, and reduced planned routine and miscellaneous 2023 capital spending by 50%.
- Re-Tain regulatory path: Four of five principal FDA technical sections were complete. The company projected a third CMC submission in Q2 2023, later than its prior end-of-April target, and anticipated an FDA response after the statutory six-month review. Management estimated commercial sales could begin about eight months after submission if the necessary FDA determinations are obtained. It anticipated FDA approval of its in-house drug-product facility during 2025.
- Re-Tain launch estimates: Under a controlled launch strategy, management estimated approximately $1 million in sales in the first year after launch and approximately twice that in the second year. Launch timing, approval, manufacturing readiness and market adoption remain uncertain.
- Debt and covenant risk: The bank waived the 2023 debt-service-coverage covenant. The company must meet a 1.35 minimum ratio for the twelve-month periods ending June 30, September 30 and December 31, 2024, and annually thereafter. Management reported the 2022 actual ratio was 0.44 and that compliance for 2022 was waived. Principal and interest obligations, weak margins, or failure to meet future covenants could constrain liquidity and investment.
- Other risks: Further contamination, supply-chain and input-cost inflation, production yields and capacity constraints, potential customer losses during the shortage, dependence on a small number of distributors, and dairy/beef market volatility could affect results. Re-Tain also depends on FDA approval and third-party supply during the transition to in-house manufacturing.
Important facts for investors to verify
- Whether contamination remediation holds, production returns to target levels, and backlog converts into shipments and sales.
- Whether the third Re-Tain CMC submission was made in Q2 2023, the FDA’s review and inspection outcomes, and the resulting launch timeline.
- Whether deferred capital projects resume, what they ultimately cost, and whether management’s production-capacity and sales goals remain feasible.
- Liquidity after repayment of the line of credit, cash burn and capital spending, and compliance with the 2024 debt-service covenants.
- Exposure to the two major distributors and significant customers, including any changes in orders, receivable collection or customer retention.